Corus CAD for Women

Assessing women for obstructive* CAD can be difficult.
Now, there’s a blood test that can help you confidently exclude this diagnosis.

With a simple blood test, you can be confident that obstructive CAD isn’t causing her symptoms.

Women with symptoms suggestive of coronary artery disease (CAD) are often more difficult to diagnose than men, due to nonspecific, atypical symptoms as well as lower performance of traditional noninvasive testing. But now, Corus® CAD provides you with the only sex-specific blood test that delivers a reliable method to exclude the diagnosis of obstructive CAD in women. Performed through a quick, routine blood draw right in your office, results are available within 72 hours.

Why does Corus CAD work?
It’s not genetics, it’s gene expression.

Whereas genetic testing provides prediction of lifetime disease risk, Corus CAD looks at the gene expression changes associated with atherosclerosis and is the only clinically validated gene expression test that provides a current-state assessment to help you exclude obstructive CAD. The test integrates expression levels of 23 genes involved in the development of and/or response to atherosclerosis as a single score, which has been proven to accurately assess obstructive CAD1,2. Integrating this test result into your evaluation provides you with a more complete picture of your patient’s disease state.

Get to the root cause.

By quickly excluding obstructive CAD as a diagnosis, you’ll be able to determine what’s behind your patient’s symptoms. You’ll also be able to keep your patient from having to undergo additional, often unnecessary and invasive diagnostic testing, and minimize her exposure to radiation from medical imaging.

Corus CAD is intended for patients** who:

  • Are NOT diabetic
  • Present with stable, typical or atypical symptoms suggestive of CAD (e.g., shortness of breath, heartburn, nausea, unexplained fatigue) without a history of CAD
  • Have not had a prior myocardial infarction (MI) or revascularization procedure
  • Are not currently taking steroids, immunosuppressive agents or chemotherapeutic agents


* Obstructive CAD is defined as at least one atherosclerotic plaque causing ≥50% luminal diameter stenosis in a major coronary artery (≥1.5 mm lumen diameter) as determined by invasive quantitative coronary angiography (QCA).
** For a complete description of the intended use population for Corus CAD, please see the Corus CAD Intended Use Statement.

  1. Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med. 2010;153:425–434.
  2. Elashoff MR, Wingrove JA, Beineke P, et al. Development of a blood-based  gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. BMC Medical Genomics. 2011;4:26.